Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Diffuse Large B Cell Lymphoma

Publisher： Bentham Science Publishers

E-ISSN：  2212-3946|12|1|14-18

ISSN： 1574-888x

Source： Current Stem Cell Research & Therapy, Vol.12, Iss.1, 2016-12, pp. : 14-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Since the improvement of chemotherapy and innovation of rituximab, about 60% of patientswith diffuse large B cell lymphoma (DLBCL) could receive long-term survival after firstline therapy.Around 30% fail to respond or experience relapse considered as the relapsed/refractory DLBCL, the highdosechemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) hasbeen used as the second-line treatment. However, the patients relapse after auto-HSCT or not eligible forthe auto-HSCT have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) isthe potentially curative way in such kind of patients. In this paper, we collected the published data aboutpatients with relapsed/refractory DLBCL who underwent allo-HSCT, demonstrated the appropriate candidatefor allo-HSCT, identified the effect of the donor types on the recipients, presented the major conditioningregimens for allo-HSCT and figured out the outcomes of each conditioning regimen. We also triedto identify the prognostic factors on the outcome which might shed some light on the further clinical application.

Related content

Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL)

By Sirohi Bhawna   Cunningham David   Norman Andy   Last Kim   Chau Ian   Horwich Alan   Oates Jacqui   Chong Geoffrey   Wotherspoon Andrew  

Hematology, Vol. 12, Iss. 2, 2007-04 ,pp. : 149-153 (5)

Maney Publishing

Access to resources Recommend Favorite

Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group

By Ito Yoshikiyo   Miyamoto Toshihiro   Kamimura Tomohiko   Takase Ken   Henzan Hideho   Sugio Yasuo   Kato Koji   Ohno Yuju   Eto Tetsuya   Teshima Takanori   Akashi Koichi  

International Journal of Hematology, Vol. 98, Iss. 4, 2013-10 ,pp. : 463-471 (9)

Springer Publishing Company

Access to resources Recommend Favorite

Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy

By Seshadri T.   Stakiw J.   Pintilie M.   Keating A.   Crump M.   Kuruvilla J.  

Hematology, Vol. 13, Iss. 5, 2008-10 ,pp. : 261-266 (6)

Maney Publishing

Access to resources Recommend Favorite

Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method

By Gutiérrez-Aguirre Cesar   Ruiz-Argüelles Guillermo   Cantú-Rodríguez Olga   González-Llano Oscar   Jaime-Pérez José   García-Rodríguez Fernando   López-Otero Avril   Herrera-Garza José   Gómez-Almaguer David  

Annals of Hematology, Vol. 89, Iss. 10, 2010-10 ,pp. : 1045-1052 (8)

Springer Publishing Company

Access to resources Recommend Favorite

Nonmyeloablative therapy and allogeneic hematopoietic stem cell transplantation

By Tabbara I.A.   Ingram R.M.  

Experimental Hematology, Vol. 31, Iss. 7, 2003-07 ,pp. : 559-566 (8)

Elsevier

Access to resources Recommend Favorite